Table 3.

Prognostic performance of the COR signature for recurrent TB disease in HIV-infected persons on ART, based on the TRuTH cohort.

Time to diagnosis	Sensitivity	Specificity	Number needed to screen∗	False positives	False negatives
WHO TPP (within 2 years of diagnosis), minimum characteristics	>75%	>75%	134	33	1
ACS COR signature 0–360 days	50%	75%	100	25	1
0–180 days	55%	75%	91	23	1
0–90 days	60%	75%	84	21	1

TTP, target product profile (World Health Organization [WHO], 2017a). ^∗Number needed to screen to detect one case of TB. For these calculations a TB prevalence of 2% was used. False positives and negatives were calculated per number screened to detect one case of TB.